Elena Wilson

250 Euston Rd
London, ENG NW12PG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Isocitrate Dehydrogenase 1/2 Wildtype Adult Astrocytoma with WHO Grade 2/3 Histological Features: Molecular Re-Classification, Prognostic Factors, Clinical Outcomes.

Isocitrate Dehydrogenase 1/2 Wildtype Adult Astrocytoma with WHO Grade 2/3 Histological Features: Molecular Re-Classification, Prognostic Factors, Clinical Outcomes.

Journal: Biomedicines

Published: January 24, 2024

Association between radiotherapy protocol variations and outcome in the CONVERT trial.

Association between radiotherapy protocol variations and outcome in the CONVERT trial.

Journal: Clinical and translational radiation oncology

Published: September 27, 2022

The impact of route of diagnosis on survival in patients with glioblastoma.

The impact of route of diagnosis on survival in patients with glioblastoma.

Journal: British journal of neurosurgery

Published: February 11, 2018

Social and structural conditions for the avoidance of advance care planning in neuro-oncology: a qualitative study.

Social and structural conditions for the avoidance of advance care planning in neuro-oncology: a qualitative study.

Journal: BMJ open

Published: February 03, 2018

Effect of accurate heart delineation on cardiac dose during the CONVERT trial.

Effect of accurate heart delineation on cardiac dose during the CONVERT trial.

Journal: The British journal of radiology

Published: April 01, 2017

Meningeal haemangiopericytoma and solitary fibrous tumour: a retrospective bi centre study for outcome and prognostic factor assessment.

Meningeal haemangiopericytoma and solitary fibrous tumour: a retrospective bi centre study for outcome and prognostic factor assessment.

Journal: Journal of neuro-oncology

Published: January 16, 2017

Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.

Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.

Journal: BMJ open

Published: January 22, 2016

WHO grade II meningioma: a retrospective study for outcome and prognostic factor assessment.

WHO grade II meningioma: a retrospective study for outcome and prognostic factor assessment.

Journal: Journal of neuro-oncology

Published: December 02, 2015

World Health Organization grade III meningiomas. A retrospective study for outcome and prognostic factors assessment.

World Health Organization grade III meningiomas. A retrospective study for outcome and prognostic factors assessment.

Journal: British journal of neurosurgery

Published: June 23, 2015

Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival.

Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival.

Journal: Journal of cancer research and clinical oncology

Published: March 22, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026